AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27020439 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted use of NOACs (group II, n = 42)
Number of subjects: 192
Study 27020439 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of vitamin K antagonist (VKA) with INR between 2.0 and 3.0 (group III, n = 43)
Number of subjects: 192
Study 27020439 — intervention group
Group type: EXPERIMENTAL
Intervention: VKA discontinuation bridged with low molecular weight heparin (group IV, n = 43)
Number of subjects: 192
Study 25190056 — intervention group
Group type: EXPERIMENTAL
Intervention: Imara intervention (three individual sessions and four phone sessions)
Number of subjects: 188
Study 25190056 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care: STI testing, treatment, and counseling)
Number of subjects: 188
Study 23158779 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum anticholinergic activity (SAA)
Number of subjects: 47
Study 23158779 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower gray matter volume in the left DLPFC
Number of subjects: 47
Study 23158779 — intervention group
Group type: EXPERIMENTAL
Intervention: SAA
Number of subjects: 47
Study 21036834 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B with 500 mL of physiologic saline and 30 mL (60 meq/L) of KCl
Number of subjects: 230
Study 21036834 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B only (1 mg/kg/day for 20 days)
Number of subjects: 230
Study 21036834 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 230
Study 18834340 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 100 microg
Number of subjects: 300
Study 18834340 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 200 microg
Number of subjects: 300
Study 18834340 — intervention group
Group type: COMPARATOR
Intervention: i.v. methylergometrine 200 microg
Number of subjects: 300
Study 16086715 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg
Number of subjects: 380
Study 16086715 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg
Number of subjects: 380
Study 16086715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 11387857 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback‐assisted relaxation training (10 sessions of weekly training)
Number of subjects: 0
Study 11387857 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 9702851 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan 300 mg twice a day for 7 days
Number of subjects: 18
Study 9702851 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice a day for 7 days
Number of subjects: 18
Study 8017472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg single dose)
Number of subjects: 18
Study 8017472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8017472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 18
Study 2574906 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with H2-receptor antagonists
Number of subjects: 140
Study 2574906 — intervention group
Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 140
Study 1165130 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ethacrynate
Number of subjects: 0
Study 1165130 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin A1 (PGA1)
Number of subjects: 0
Study 1165130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31132182 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, applied twice daily for 28 days.
Number of subjects: 1522
Study 31132182 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control group), applied twice daily for 28 days.
Number of subjects: 1522
Study 29295296 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS messages
Number of subjects: 73
Study 26003642 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing injection (100 mL once a day for 7 days)
Number of subjects: 62
Study 26003642 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 62
Study 22289020 — intervention group
Group type: EXPERIMENTAL
Intervention: R2 diet (50% concentrate mixture and 50% tree foliages)
Number of subjects: 20
Study 22289020 — intervention group
Group type: EXPERIMENTAL
Intervention: R3 diet (50% concentrate mixture and 50% rice straw)
Number of subjects: 20
Study 22289020 — intervention group
Group type: EXPERIMENTAL
Intervention: R4 diet (50% concentrate mixture, 25% tree foliages, and 25% rice straw)
Number of subjects: 20
Study 22289020 — intervention group
Group type: COMPARATOR
Intervention: R1 diet (tree foliages only)
Number of subjects: 20
Study 21304148 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT)
Number of subjects: 323
Study 21304148 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release oxycodone
Number of subjects: 323
Study 19298620 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in a proposed emergency treatment trial for SAH
Number of subjects: 905
Study 19298620 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic characteristics (age, sex, race/ethnicity, education, religion, clinical setting, reason for visit, history of neurologic injury)
Number of subjects: 905
Study 19298620 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of family member as proxy decision-maker
Number of subjects: 905
Study 16520413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bone marrow cell (BMC) transfer
Number of subjects: 60
Study 16520413 — intervention group
Group type: COMPARATOR
Intervention: Optimal postinfarction therapy (Control)
Number of subjects: 60
Study 15248624 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcuff endotracheal tube
Number of subjects: 50
Study 15248624 — intervention group
Group type: COMPARATOR
Intervention: Conventional endotracheal tubes (Mallinckrodt HiLo, Portex Profile Soft Seal, Rüsch Super Safety Clear, Sheridan CF)
Number of subjects: 50
Study 10950800 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 300 microg/day
Number of subjects: 480
Study 10950800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 8644584 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sheath
Number of subjects: 60
Study 8644584 — intervention group
Group type: COMPARATOR
Intervention: Nonflexible sheath
Number of subjects: 60
Study 1630805 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment for chronic type B hepatitis
Number of subjects: 0
Study 1630805 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment for chronic type C hepatitis
Number of subjects: 0
Study 1630805 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment for hepatitis Delta infection
Number of subjects: 0
Study 6368141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 0.4 mg
Number of subjects: 12
Study 6368141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 0.8 mg
Number of subjects: 12
Study 6368141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31900843 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium plus budesonide
Number of subjects: 180
Study 31900843 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (control group)
Number of subjects: 180
Study 29136096 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized design (larger and red)
Number of subjects: 646
Study 29136096 — intervention group
Group type: COMPARATOR
Intervention: Current in market alcohol warning label
Number of subjects: 646
Study 29136096 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported attention for optimized design
Number of subjects: 646
Study 26139005 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP+MTX
Number of subjects: 316
Study 26425812 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants (6 mm)
Number of subjects: 97
Study 26425812 — intervention group
Group type: COMPARATOR
Intervention: Long implants (11-15 mm) with sinus grafting
Number of subjects: 97
Study 23833852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.165% with fentanyl 2.0 micro g/ml
Number of subjects: 70
Study 23833852 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine 0.125% with fentanyl 2.0 micro g/ml
Number of subjects: 70
Study 21092287 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alpha‐2b (40‐kDa), single 180 micrograms dose, subcutaneously administered
Number of subjects: 16
Study 21092287 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN alpha‐2a (reference), single 180 micrograms dose, subcutaneously administered
Number of subjects: 16
Study 21092287 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 16
Study 18206917 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 655
Study 18206917 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous rectus sling
Number of subjects: 655
Study 18206917 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 655
Study 16628153 — intervention group
Group type: EXPERIMENTAL
Intervention: Blink reflex (BR) evaluation in diabetic patients with PN
Number of subjects: 188
Study 16628153 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 188
Study 16628153 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of R1, IR2, and CR2 latencies
Number of subjects: 188
Study 16628153 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine nerve conduction studies
Number of subjects: 188
Study 12884193 — intervention group
Group type: EXPERIMENTAL
Intervention: Celsior solution (CS)
Number of subjects: 173
Study 12884193 — intervention group
Group type: COMPARATOR
Intervention: University of Wisconsin solution (UW)
Number of subjects: 173
Study 10640263 — intervention group
Group type: EXPERIMENTAL
Intervention: pivampicillin plus pivmecillinam (40 mg/kg/day and 50 mg/kg/day respectively)
Number of subjects: 56
Study 10640263 — intervention group
Group type: COMPARATOR
Intervention: pivampicillin (50 mg/kg/day)
Number of subjects: 56
Study 10640263 — intervention group
Group type: EXPERIMENTAL
Intervention: pivampicillin plus pivmecillinam
Number of subjects: 56
Study 10640263 — intervention group
Group type: COMPARATOR
Intervention: pivampicillin
Number of subjects: 56
Study 8881083 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 8881083 — intervention group
Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 0
Study 2060415 — intervention group
Group type: EXPERIMENTAL
Intervention: Telematic transmission of computerized SMBG
Number of subjects: 22
Study 2060415 — intervention group
Group type: COMPARATOR
Intervention: Traditional booklets for SMBG
Number of subjects: 22
Study 6230883 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimeldine
Number of subjects: 263
Study 6230883 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 263
Study 6230883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 3932049 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 100 micrograms administered q.i.d. for up to four weeks
Number of subjects: 286
Study 3932049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 3932049 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 286
Study 29660425 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab 400 mg every 2 weeks for 16 weeks
Number of subjects: 0
Study 29660425 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab 200 mg every 2 weeks for 16 weeks
Number of subjects: 0
Study 29660425 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 2 weeks for 16 weeks
Number of subjects: 0
Study 29660425 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg twice weekly for 12 weeks
Number of subjects: 0
Study 27096428 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-Glucose (EG)
Number of subjects: 4
Study 27096428 — intervention group
Group type: COMPARATOR
Intervention: Rest-Glucose (RG)
Number of subjects: 4
Study 27096428 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-Fructose (EF)
Number of subjects: 4
Study 27096428 — intervention group
Group type: COMPARATOR
Intervention: Rest-Fructose (RF)
Number of subjects: 4
Study 24968000 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg moxidectin
Number of subjects: 172
Study 24968000 — intervention group
Group type: COMPARATOR
Intervention: ivermectin
Number of subjects: 172
Study 21846661 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS) with brief repeated behavioral intervention (BRBI)
Number of subjects: 246
Study 21846661 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch with brief repeated behavioral intervention (BRBI)
Number of subjects: 246
Study 20671013 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplements (≥500 mg/day)
Number of subjects: 20172
Study 18209721 — intervention group
Group type: EXPERIMENTAL
Intervention: DNAemia cutoff of 10,000 copies per ml whole blood
Number of subjects: 83
Study 18209721 — intervention group
Group type: COMPARATOR
Intervention: Antigenemia positivity for initiation of preemptive therapy
Number of subjects: 83
Study 16174075 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocytapheresis (LCAP)
Number of subjects: 29
Study 16174075 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (PSL)
Number of subjects: 29
Study 12556541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (multifactorial intervention targeting hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, along with secondary prevention with aspirin)
Number of subjects: 160
Study 12556541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 160
Study 12556541 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 160
Study 10644551 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion at 6 mg x kg(‐1) x min(‐1)
Number of subjects: 6
Study 10644551 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion at 2 mg x kg(‐1) x min(‐1)
Number of subjects: 6
Study 10644551 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose pulse induction (6 mg x kg(‐1) x min(‐1))
Number of subjects: 6
Study 9008993 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tack chewing gum
Number of subjects: 50
Study 9008993 — intervention group
Group type: COMPARATOR
Intervention: Regular-tack chewing gum
Number of subjects: 50
Study 1653671 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (320 fmol/min)
Number of subjects: 14
Study 1653671 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 14
Study 6301262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid for 4 weeks
Number of subjects: 71
Study 6301262 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 71
Study 6301262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid for up to 8 weeks (after initial 4 weeks of placebo for unhealed patients)
Number of subjects: 71
Study 31515680 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic Surgery (RS)
Number of subjects: 12
Study 31515680 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Surgery (LS)
Number of subjects: 12
Study 31515680 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Surgery (LS) to Robotic Surgery (RS) transfer effect
Number of subjects: 12
Study 30866837 — intervention group
Group type: EXPERIMENTAL
Intervention: End-ischemic dual hypothermic oxygenated machine perfusion (DHOPE) for 2 hours after static cold storage (SCS) before implantation.
Number of subjects: 0
Study 30866837 — intervention group
Group type: COMPARATOR
Intervention: Conventional static cold storage (SCS) only.
Number of subjects: 0
Study 27480499 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination (DRE) posterior surface area estimates
Number of subjects: 30500
Study 27480499 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of DRE posterior surface area
Number of subjects: 30500
Study 27480499 — intervention group
Group type: EXPERIMENTAL
Intervention: DRE posterior surface area
Number of subjects: 30500
Study 25370155 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment for 4 weeks
Number of subjects: 0
Study 25370155 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25370155 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 0
Study 23288881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin (EZ/S) 10/20 mg
Number of subjects: 0
Study 23288881 — intervention group
Group type: COMPARATOR
Intervention: Doubling the run-in statin dose (to simvastatin 40 mg or atorvastatin 20 mg)
Number of subjects: 0
Study 23288881 — intervention group
Group type: COMPARATOR
Intervention: Switching to rosuvastatin 10 mg
Number of subjects: 0
Study 22282731 — intervention group
Group type: EXPERIMENTAL
Intervention: All-ceramic (AC) restorations
Number of subjects: 36
Study 22282731 — intervention group
Group type: COMPARATOR
Intervention: Metal-ceramic (MC) restorations
Number of subjects: 36
Study 22282731 — intervention group
Group type: EXPERIMENTAL
Intervention: All-ceramic (AC) crowns
Number of subjects: 36
Study 22282731 — intervention group
Group type: COMPARATOR
Intervention: Metal-ceramic (MC) crowns
Number of subjects: 36
Study 19421684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 56
Study 19421684 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 56
Study 16719649 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants learning in a four-cue probabilistic environment
Number of subjects: 0
Study 16719649 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning analyses using rolling regression methods
Number of subjects: 0
Study 14996137 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (long-term treatment)
Number of subjects: 0
Study 14996137 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (short-term treatment)
Number of subjects: 0
Study 14996137 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex (short-term treatment)
Number of subjects: 0
Study 14996137 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (short-term treatment)
Number of subjects: 0
Study 14996137 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (short-term treatment)
Number of subjects: 0
Study 14996137 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (long-term treatment)
Number of subjects: 0
Study 12575569 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) plus bronchial arterial infusion chemotherapy (BAIC)
Number of subjects: 76
Study 12575569 — intervention group
Group type: COMPARATOR
Intervention: Bronchial arterial infusion chemotherapy (BAIC) alone
Number of subjects: 76
Study 9918434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin plus IFNα
Number of subjects: 8
Study 9918434 — intervention group
Group type: COMPARATOR
Intervention: IFNα alone
Number of subjects: 8
Study 7848794 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiautomatic blood pressure measuring device (UA‐751)
Number of subjects: 156
Study 7848794 — intervention group
Group type: COMPARATOR
Intervention: Standard mercury sphygmomanometer (physician readings)
Number of subjects: 156
Study 3243913 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 16 mg dose
Number of subjects: 12
Study 3243913 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg dose given hourly for 10 doses
Number of subjects: 12
Study 3243913 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial dose of 4.8 mg, followed by 1.6 mg doses given every hour for seven additional doses
Number of subjects: 12
Study 3243913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing regimen 1
Number of subjects: 12
Study 3243913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing regimen 2
Number of subjects: 12
Study 3243913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing regimen 3
Number of subjects: 12
Study 30626409 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intramuscular scopolamine augmentation
Number of subjects: 66
Study 30626409 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intramuscular scopolamine augmentation
Number of subjects: 66
Study 30626409 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 66
Study 27641483 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based air cleaner intervention
Number of subjects: 25
Study 25796459 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.8 mg/kg, 16 cycles, IV every 3 weeks)
Number of subjects: 329
Study 25796459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study 25796459 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 329
Study 22615325 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced group (motivational interview with air quality data at visit 2)
Number of subjects: 59
Study 22615325 — intervention group
Group type: COMPARATOR
Intervention: Control group (motivational interview with air quality data at visit 4)
Number of subjects: 59
Study 21730077 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6-MP)
Number of subjects: 0
Study 21730077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19319941 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load
Number of subjects: 84
Study 19319941 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral replication capacity
Number of subjects: 84
Study 19319941 — intervention group
Group type: COMPARATOR
Intervention: Maternal humoral immune response
Number of subjects: 84
Study 16964670 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (Engerix‐B SKB 20 microg) administered according to a 0, 1, 2 month regime.
Number of subjects: 29
Study 14960293 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz, 110% of motor threshold, 20 trains of 5 seconds duration)
Number of subjects: 0